PEOPLE - changes at IDMoS:
This article was originally published in Clinica
Executive Summary
UK-listed disease detection and monitoring technology specialist IDMoS has appointed non-executive chairman John Pool to interim executive chairman, following CEO Stephen Westwood's decision to leave with immediate effect to pursue other business interests. The board intends to appoint Johnson & Johnson veteran Graham Lay as COO as of mid-July. A new CEO will be appointed "as soon as practical", said the Dundee company.
You may also be interested in...
Probiotics And Cold Remedies Boost Recordati In 2023
Italy's Recordati saw its OTC sales grow by 10% in 2023 driven by the recovery of the cough & cold market and a growing demand for probiotics.
Falling Sales Force New Priorities At Roche
The Swiss major brings a new ruthlessness to the compounds in its pipeline: if they’re not first or best, they’re out.
Human Cell-Secreted Proteins Offer A Wellspring Of Potential Therapeutics
CEO Hanadie Yousef leads Juvena Therapeutics in utilizing an AI-based platform that analyzes cell-secreted proteins to identify potential therapeutics. One of their first near-clinical assets could complement GLP-1s.